• 1
    Halpern J. H., Sherwood A. R., Hudson J. I., Gruber S., Kozin D., Pope H. G. Jr. Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction 2011; 106: 77786.
  • 2
    Lyvers M., Hasking P. Have Halpern et al. (2004) detected ‘residual neuropsychological effects’ of MDMA? Not likely. Drug Alcohol Depend 2004; 75: 14952.
  • 3
    Halpern J. H., Pope H. G. Jr., Sherwood A. R., Barry S., Hudson J. I., Yurgelun-Todd D. Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004; 75: 13547.
  • 4
    Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of methylenedioxymethamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101: 34861.
  • 5
    Hanson K. L., Luciana M. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor. J Clin Exp Neuropsychol 2010; 32: 33749.
  • 6
    Jager G., de Win M. M. L., van der Tweet I., Schilt T., Kahn R. S., van den Brink W. et al. Assessment of cognitive brain function in ecstasy users and contributions of other drugs of abuse: results from an fMRI study. Neuropsychopharmacology 2008; 33: 24758.
  • 7
    Lyvers M. Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues. Drug Alcohol Rev 2006; 25: 26976.
  • 8
    Levine B., Dawson D., Boutet I., Schwartz M. L., Stuss D. T. Assessment of strategic self-regulation in traumatic brain injury: its relationship to injury severity and psychosocial outcome. Neuropsychology 2000; 14: 491500.
  • 9
    Kreek M. J., Nielsen D. A., Butelman E. R., LaForge K. S. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005; 8: 145057.
  • 10
    Chen A. C. H., Porjesz B., Rangaswamy M., Kamarajan C., Tang Y., Jones K. A. et al. Reduced frontal lobe activity in subjects with high impulsivity and alcoholism. Alcohol Clin Exp Res 2007; 31: 15665.
  • 11
    Lyvers M., Duff H., Hasking P. Risky alcohol use and age at onset of regular alcohol consumption in relation to frontal lobe indices, reward sensitivity and rash impulsiveness. Addict Res Theory 2010; Epub ahead of print.
  • 12
    Schilt T., Goudriaan A. E., Koeter M. W., van den Brink W., Schmand B. Decision making as a predictor of first ecstasy use: a prospective study. Psychopharmacologia 2009; 203: 51927.
  • 13
    Allott K., Canny B. J., Broadbear J. H., Stepto N. K., Murphy B., Redman J. Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users. J Psychopharmacol 2009; 23: 75974.
  • 14
    O'Donnell J. T. Drug Injury: Liability, Analysis and Prevention. Tucson: Lawyers & Judges Publishing; 2005.
  • 15
    McCann U. D., Szabo Z., Vranesic M., Seckin E., Wand G., DuVal A. et al. Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluramine. Mol Imaging Biol 2007; 9: 15157.
  • 16
    Thomasius R., Petersen K., Buchert R., Andresen B., Zapletalova P., Wartberg L. et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 2003; 167: 8596.
  • 17
    Ludewig S., Ludewig K., Hasler F., Vollenweider F. X. No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in healthy humans. Biol Psychiatry 2003; 53: 205S.
  • 18
    Mithoefer M. C., Wagner M. T., Mithoefer A. T., Jerome L., Doblin R. The safety and efficacy of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2010. Epub ahead of print, 19 July.